Using autoantibody signatures to define cancer risk in dermatomyositis

Dermatomyositis is an idiopathic inflammatory myopathy with a highly heterogeneous disease course. Although there is a known increase in cancer risk surrounding the time of dermatomyositis diagnosis, the mechanisms driving this increased risk are not well understood. Further, there are no current st...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 132; no. 2; pp. 1 - 3
Main Authors Turnier, Jessica L, Kahlenberg, J Michelle
Format Journal Article
LanguageEnglish
Published Ann Arbor American Society for Clinical Investigation 01.01.2022
Subjects
Antibodies
Antigens
Apoptosis
Autoantibodies
Biomedical research
Cancer
Cancer screening
Cancer therapies
Cell division
Dermatomyositis
Diagnosis
Gene expression
Genotype & phenotype
Immune response
Inflammation
Malignancy
Medical screening
Melanoma
Myopathy
Ovarian cancer
Patients
Phenotyping
Proteins
Risk factors
Scleroderma
Skin diseases
Online AccessGet full text

Cover

More Information
Summary:Dermatomyositis is an idiopathic inflammatory myopathy with a highly heterogeneous disease course. Although there is a known increase in cancer risk surrounding the time of dermatomyositis diagnosis, the mechanisms driving this increased risk are not well understood. Further, there are no current standardized cancer screening guidelines for dermatomyositis patients. In this issue of the JCI, Fiorentino, Mecoli, et al. discovered additional autoantibodies in patients with dermatomyositis and anti-TIF1-γ autoantibodies, a known risk factor for malignancy. They observed a decreased cancer risk with an increasing number of autoantibodies. Importantly, these findings indicate that more detailed autoantibody phenotyping at diagnosis might better predict cancer risk and also suggest that diversity and kinetics of the host immune response might influence cancer development.
ISSN:0021-9738
1558-8238
DOI:10.1172/JCI150201